Chemotherapy (Antibiotics): DNA and RNA Synthesis Inhibitors

Introduction/Overview

DNA and RNA synthesis inhibitors constitute a pivotal class of antitumor antibiotics that disrupt nucleic acid metabolism, thereby impeding cellular proliferation. Their therapeutic utility extends across a spectrum of malignancies, from solid tumors to hematologic cancers, and they are often employed in combination regimens to enhance efficacy and mitigate resistance. Understanding the nuanced pharmacology of these agents is essential for rational clinical application and for anticipating adverse events that can limit therapeutic windows.

Clinical relevance is underscored by the prevalence of chemotherapeutic failure arising from drug resistance and toxicity. Consequently, a comprehensive grasp of pharmacodynamics, pharmacokinetics, and patient-specific factors informs dose optimization and supportive care strategies. This chapter aims to consolidate current knowledge on DNA and RNA synthesis inhibitors, with a focus on antitumor antibiotics, to equip medical and pharmacy students with a robust conceptual framework for clinical decision‑making.

Learning Objectives

• Identify the major classes of DNA and RNA synthesis‑inhibiting antitumor antibiotics and their chemical origins.
• Explain the molecular mechanisms underlying the inhibition of nucleic acid synthesis by these agents.
• Describe the pharmacokinetic profiles of key drugs, including absorption routes, distribution patterns, metabolic pathways, and excretion mechanisms.
• Recognize approved therapeutic indications and common off‑label uses for each drug class.
• Outline major adverse effects, drug interactions, and special population considerations to guide safe prescribing.

Classification

Drug Classes and Categories

Antitumor antibiotics that interfere with nucleic acid synthesis are broadly categorized as follows:

• Antimetabolites – Structural analogues of natural nucleosides or nucleobases that competitively inhibit key enzymes in de novo nucleotide synthesis (e.g., 5‑fluorouracil, gemcitabine, methotrexate).
• Alkylating agents – Electrophilic compounds that induce cross‑linking of DNA strands, impeding replication and transcription (e.g., cyclophosphamide, ifosfamide, melphalan, busulfan).
• Topoisomerase inhibitors – Agents that stabilize the transient DNA‑topoisomerase complex, preventing re-ligation and resulting in DNA strand breaks (e.g., topotecan, irinotecan, doxorubicin, epirubicin).
• RNA polymerase inhibitors – Antibiotics that bind to the DNA–RNA complex or the active site of RNA polymerase, blocking transcription (e.g., actinomycin D, mitomycin C).
• Intercalating agents – Molecules that insert between DNA base pairs, distorting the helix and inhibiting replication and transcription (e.g., doxorubicin, daunorubicin).

Chemical Classification

These agents can also be grouped by their structural families:

• Platinum complexes (e.g., cisplatin, carboplatin, oxaliplatin) – Coordinate with DNA bases to form cross‑links.
• Anthracyclines (e.g., doxorubicin, epirubicin, daunorubicin) – Macrocyclic lactones that intercalate DNA and generate free radicals.
• Camptothecins (e.g., topotecan, irinotecan) – Lactone-containing alkaloids that inhibit topoisomerase I.
• Pyrimidine analogues (e.g., gemcitabine, cytarabine) – Fluorinated or deoxycytidine derivatives that disrupt DNA synthesis.
• Purine analogues (e.g., fludarabine, cladribine) – Modified adenine nucleotides that impede DNA polymerase activity.

Mechanism of Action

Antimetabolites

Antimetabolites mimic endogenous substrates of nucleotide biosynthetic enzymes. 5‑Fluorouracil (5‑FU) is converted intracellularly to fluorodeoxyuridine monophosphate (FdUMP), which forms a stable ternary complex with thymidylate synthase and 5,10‑methylene‑tetrahydrofolate. This complex inhibits the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), leading to thymidylate depletion and dTTP starvation. Consequently, DNA synthesis stalls, and misincorporation of uracil into DNA triggers mismatch repair pathways, culminating in apoptosis.

Gemcitabine, a deoxycytidine analogue, undergoes phosphorylation to gemcitabine triphosphate (dFdCTP). dFdCTP competes with deoxycytidine triphosphate (dCTP) for incorporation by DNA polymerase. Additionally, gemcitabine induces “masked chain termination,” where incorporation of a single gemcitabine mononucleotide prevents further extension. The resulting depletion of dCTP pools further impairs DNA synthesis.

Methotrexate (MTX) competitively inhibits dihydrofolate reductase (DHFR), reducing tetrahydrofolate production and subsequently limiting purine and thymidylate synthesis. This double blockade reduces the availability of nucleotides required for DNA synthesis.

Alkylating Agents

Alkylating agents transfer alkyl groups to nucleophilic sites on DNA bases, predominantly forming cross‑links between nucleophilic nitrogen atoms. Cyclophosphamide, after hepatic activation to phosphoramide mustard, induces interstrand cross‑links that prevent strand separation during replication. The resulting DNA damage activates the p53 pathway and triggers apoptosis.

Melphalan (Lomustine) forms monofunctional and bifunctional alkyl groups, leading to base mispairing and strand breaks. The alkylation pattern is less uniform than that of nitrogen mustards, but the overall effect is comparable: disruption of DNA helix integrity and inhibition of replication.

Topoisomerase Inhibitors

Topoisomerase I inhibitors (topotecan, irinotecan) trap the enzyme–DNA cleavage complex by stabilizing the transient single‑strand break. This prevents re‑ligation of the DNA backbone, resulting in accumulation of single‑strand breaks that, during replication, are converted to lethal double‑strand breaks.

Topoisomerase II inhibitors (anthracyclines, epipodophyllotoxins) stabilize the cleavable complex formed during the catalytic cycle of DNA unwinding. The resultant double‑strand breaks activate DNA damage checkpoints and apoptosis pathways. Doxorubicin also generates reactive oxygen species via redox cycling, contributing to its cytotoxicity.

RNA Polymerase Inhibitors

Actinomycin D binds to the DNA–RNA hybrid within the transcription bubble, preventing the elongation of the RNA chain. The antibiotic is intercalated at the +1 position of the transcription initiation complex, physically blocking RNA polymerase progression. Mitomycin C, a bifunctional alkylating agent, also cross‑links DNA but is noted for its ability to impede transcription by inducing DNA lesions that stall RNA polymerase.

Pharmacokinetics

Absorption

Most DNA and RNA synthesis inhibitors are administered intravenously to circumvent first‑pass metabolism and variable oral bioavailability. 5‑FU can be given orally as capecitabine, a prodrug that undergoes enzymatic conversion to 5‑FU in the tumor microenvironment, enhancing local drug concentrations.

Distribution

Distribution is influenced by plasma protein binding, lipophilicity, and tissue affinity. Anthracyclines exhibit high plasma protein binding (~70–80%) and extensive tissue distribution, including the heart and leukocytes. Alkylating agents generally display moderate protein binding and distribute widely, with notable accumulation in bone marrow and renal excretion pathways.

Metabolism

Metabolic pathways vary among agents:

• Cisplatin is largely excreted unchanged; carboplatin is metabolized via hydrolysis to a reactive carboplatin species.
• Topotecan is metabolized by cytochrome P450 (CYP3A4) and carboxylesterases.
• Gemcitabine is deaminated to 2‑deoxy‑5‑fluorocytidine by cytidine deaminase, limiting its half‑life.
• MTX is cleared by renal excretion; hepatic metabolism is minimal.

Excretion

Renal excretion predominates for many agents. Cyclophosphamide metabolites are eliminated renally, whereas melphalan is primarily excreted unchanged in urine. Doxorubicin is metabolized to doxorubicinol and other metabolites, which are excreted via bile and urine. The half‑life ranges from 48 hours for doxorubicin, influencing dosing intervals.

Dosing Considerations

• Body surface area (BSA) calculations are standard for many cytotoxic agents to normalize dose distribution.
• Therapeutic drug monitoring (TDM) may be employed for agents with narrow therapeutic indices (e.g., MTX, 5‑FU).
• Combination regimens often require dose adjustments to account for overlapping toxicities and pharmacokinetic interactions.

Therapeutic Uses/Clinical Applications

Approved Indications

DNA and RNA synthesis inhibitors are indicated for a variety of malignancies:

• 5‑FU and capecitabine: colorectal, breast, head and neck cancers.
• Gemcitabine: pancreatic, non‑small cell lung, bladder cancers.
• Cisplatin, carboplatin, oxaliplatin: testicular, ovarian, lung, colorectal, gastric cancers.
• Anthracyclines: acute lymphoblastic leukemia, breast cancer, soft tissue sarcomas.
• Topoisomerase inhibitors: colorectal, ovarian, breast, hematologic malignancies.
• Actinomycin D: pediatric cancers, e.g., rhabdomyosarcoma.

Off‑Label Uses

Clinical practice often incorporates these agents beyond approved indications:

• Melphalan in conditioning regimens for autologous stem cell transplantation.
• Gemcitabine as a second‑line therapy in metastatic breast cancer.
• Do‑xorubicin in combination with trastuzumab for HER2‑positive breast cancer.
• Topotecan in relapsed small cell lung cancer.

Adverse Effects

Common Side Effects

Acute toxicity is frequently dose‑dependent and includes myelosuppression, mucositis, alopecia, and gastrointestinal disturbances. Specific agents have characteristic profiles:

• 5‑FU: hand‑foot syndrome, diarrhea, neurotoxicity.
• Gemcitabine: flu‑like symptoms, liver enzyme elevation.
• Cisplatin: nephrotoxicity, neurotoxicity, ototoxicity.
• Anthracyclines: cardiomyopathy, arrhythmias, alopecia.
• Topotecan: severe myelosuppression, gastrointestinal toxicity.

Serious/ Rare Adverse Reactions

Serious reactions include:

• Cardiotoxicity from anthracyclines, leading to congestive heart failure.
• Vascular occlusion syndrome from gemcitabine, especially in patients with pre‑existing vascular disease.
• Severe renal impairment from cisplatin in patients with pre‑existing kidney disease.
• Secondary malignancies, particularly from alkylating agents and topoisomerase inhibitors.

Black Box Warnings

Key agents with black box warnings:

• Cisplatin and carboplatin: risk of hearing loss and nephrotoxicity.
• Anthracyclines: cumulative dose‑related cardiotoxicity.
• Topotecan: profound myelosuppression requiring close monitoring.
• Gemcitabine: risk of vascular thromboembolic events.

Drug Interactions

Major Drug–Drug Interactions

Several interactions can potentiate toxicity or reduce efficacy:

• Concomitant use of carboplatin with nephrotoxic agents (e.g., aminoglycosides, NSAIDs) increases renal injury risk.
• Topotecan and strong CYP3A4 inhibitors (e.g., ketoconazole) elevate plasma concentrations, raising myelosuppression risk.
• Anthracyclines combined with other cardiotoxic drugs (e.g., trastuzumab) amplify cardiac risk.
• Gemcitabine and drugs that inhibit cytidine deaminase may increase exposure.

Contraindications

Contraindications include:

• Severe renal or hepatic impairment for agents predominantly cleared by these organs.
• Pregnancy for most DNA/RNA synthesis inhibitors due to teratogenicity.
• Active infections in patients with profound neutropenia.
• Pre‑existing cardiomyopathy for anthracyclines.

Special Considerations

Use in Pregnancy/Lactation

These agents are classified as category D or X in many pregnancy classification systems, implying potential fetal harm. Breastfeeding is generally contraindicated due to drug excretion into milk and the risk of systemic toxicity in nursing infants.

Pediatric/Geriatric Considerations

Pediatric dosing often requires careful adjustment for body weight and developmental pharmacokinetics. Geriatric patients may exhibit reduced renal clearance and increased susceptibility to cardiotoxicity; dose reductions and enhanced monitoring are advisable.

Renal/Hepatic Impairment

Agents primarily eliminated by the kidneys (e.g., cisplatin, gemcitabine) necessitate dose modifications proportional to glomerular filtration rate. Hepatic impairment affects metabolism of drugs such as topotecan and anthracyclines; dose adjustment or alternative agents may be required.

Summary/Key Points

• DNA and RNA synthesis inhibitors are cornerstone antitumor antibiotics, functioning primarily by disrupting nucleotide metabolism and DNA integrity.
• Mechanistic diversity—ranging from antimetabolite competition to topoisomerase stabilization—underlies their broad therapeutic spectrum.
• Pharmacokinetic profiles dictate administration routes, dosing intervals, and the necessity for monitoring, particularly for agents with narrow therapeutic indices.
• Adverse effect profiles are agent‑specific; cardiotoxicity, nephrotoxicity, and myelosuppression are common concerns requiring vigilant surveillance.
• Drug interactions mediated by shared metabolic pathways may amplify toxicity; concurrent use with nephrotoxic or cardiotoxic agents warrants dose adjustments or alternative therapies.
• Special populations—including pregnant women, nursing mothers, the elderly, and those with organ dysfunction—require individualized dosing and monitoring strategies.

Clinical pearls include:

• Pre‑treatment cardiac evaluation is advisable before anthracycline therapy.
• Hydration protocols mitigate cisplatin‑induced nephrotoxicity.
• Monitoring complete blood counts (CBC) is essential for timely detection of myelosuppression across all agents.
• Avoidance of concomitant nephrotoxic drugs during cisplatin or carboplatin therapy reduces renal injury risk.
• Use of folinic acid rescue with high‑dose 5‑FU or leucovorin with methotrexate can reduce toxicity without compromising efficacy.

Incorporating these principles into clinical practice optimizes therapeutic outcomes while minimizing harm for patients receiving DNA and RNA synthesis‑inhibiting chemotherapy.

References

1. Gilbert DN, Chambers HF, Saag MS, Pavia AT. The Sanford Guide to Antimicrobial Therapy. 53rd ed. Sperryville, VA: Antimicrobial Therapy Inc; 2023.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.